Trials / Completed
CompletedNCT02729025
Effects of Proprotein Convertase Subtilisin/Kexin Type 9 (PCSK9) Inhibition on Arterial Wall Inflammation in Patients With Elevated Lipoprotein(a) (Lp(a))
A RaNdomized Double-blInd Placebo ConTrolled Study Characterizing THe Effects of PCSK9 Inhibition On Arterial Wall Inflammation in Patients With Elevated Lp(a) (ANITSCHKOW)
- Status
- Completed
- Phase
- Phase 3
- Study type
- Interventional
- Enrollment
- 129 (actual)
- Sponsor
- Amgen · Industry
- Sex
- All
- Age
- 50 Years – 80 Years
- Healthy volunteers
- Not accepted
Summary
A study to assess the effects of proprotein convertase subtilisin/ kexin type 9 (PCSK9) inhibition on the arterial wall inflammation in patients with elevated lipoprotein(a).
Conditions
Interventions
| Type | Name | Description |
|---|---|---|
| DRUG | Evolocumab | Administered subcutaneously once a month using an autoinjector/pen. |
| DRUG | Placebo | Administered subcutaneously once a month using an autoinjector/pen. |
Timeline
- Start date
- 2016-04-14
- Primary completion
- 2018-04-05
- Completion
- 2018-04-05
- First posted
- 2016-04-06
- Last updated
- 2022-09-23
- Results posted
- 2019-04-23
Locations
15 sites across 3 countries: United States, Canada, Netherlands
Source: ClinicalTrials.gov record NCT02729025. Inclusion in this directory is not an endorsement.